Biocon has been granted a patent for a humanized IgG1 anti-CD6 antibody (T1h) that targets the SRCR domain 1 of CD6 on various immune cells. The patent claims a specific monoclonal antibody with defined heavy and light chain variable sequences. GlobalData’s report on Biocon gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biocon, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Biocon's grant share as of June 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized igg1 anti-cd6 monoclonal antibody
The granted patent US11981743B2 describes a humanized IgG1 monoclonal antibody that specifically targets human CD6. The antibody is characterized by a heavy chain variable (VH) sequence and a light chain variable (VK) sequence, as detailed in the provided sequences SEQ ID NO:1 and SEQ ID NO:2. This antibody is proposed for therapeutic applications, particularly in the treatment of graft-versus-host disease (GVHD), a condition that can occur after stem cell or organ transplants when the donor's immune cells attack the recipient's body.
In addition to GVHD, the patent outlines methods for using the humanized IgG1 monoclonal antibody to inhibit T cell proliferation in patients with various diseases and disorders. These include transplant rejection, psoriasis, rheumatoid arthritis, type-1 diabetes, cutaneous T cell lymphoma, thyroiditis, and autoimmune encephalomyelitis. The claims specify that the antibody can be administered to treat each of these conditions, highlighting its potential versatility in addressing multiple immune-related disorders.
To know more about GlobalData’s detailed insights on Biocon, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
